At 11 years old, Jaheim Whigham (center) is the youngest and smallest patient to receive the 50cc SynCardia temporary Total Artificial Heart. (Photo: Jan Terry, Ann & Robert H. Lurie Children’s Hospital of Chicago)Continue reading
Category Archives: AZBio News
Hearst Foundation funds TGen research into cancer-related ‘wasting syndrome’
Cachexia responsible for more than 30 percent of deaths in cancer patients
SenesTech is Ramping Things Up
SenesTech, Inc. (SNES), a developer of proprietary technologies for managing animal pest populations through fertility control is ramping up manufacturing capabilities to meet demand in 2017 and beyond for the company’s innovative new rodent control technology, ContraPest. The Company’s existing manufacturing capacity, estimated at 300,000 liters per year, is expected to double under the current expansion plans.Continue reading
Venture Madness: Give Our AZBio Members a Thumbs Up
2017 VENTURE MADNESS COMPETITION – VOTE FOR THE PEOPLE’S CHOICE AWARD by 5:00 PM, on January 24thContinue reading
Applications are Open for the Spring 2017 Arizona Innovation Challenge
Submission Window Open through February 17th!!Continue reading
SenesTech Rings the Closing Bell at Nasdaq.
SenesTech, Inc. (Nasdaq: SNES), a developer of novel proprietary technologies for managing animal pest populations through fertility control, visited the Nasdaq MarketSite in Times Square to ring the closing bell on Friday, January 20, 2017.Continue reading
It’s Time to Apply for MedTech Innovator
Applications for 2017 Are Now OpenContinue reading
Castle Biosciences’ New Laboratory Receives Accreditation from College of American Pathologists
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its new state-of-the-art laboratory facility in Phoenix, AZ based on results of a recent onsite inspection as part of the CAP’s Accreditation Programs.
TGen identifies compound that could improve drug development against deadly brain cancer
ATA prevents glioblastoma cells from spreading, and leave them vulnerable to chemotherapy and radiation
Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study
Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“JV”) announced today that the JV’s lead commercial drug candidate, AEM-28-14, showed substantial and statistically-significant LDL cholesterol (LDLc) reductions in a hypercholesterolemic primate study at Wake Forest University. Following a single IV administration of escalating doses up to 5mg/kg, LDLc exhibited a mean reduction of 64% from baseline at 24 hours, 46% from baseline at 3 days and 16% from baseline at 7 days, despite the study animals remaining on a high fat/cholesterol diet through the full study.